Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Jul;34(4):656-63.
doi: 10.1093/schbul/sbn042. Epub 2008 May 20.

Implementation considerations for multisite clinical trials with cognitive neuroscience tasks

Affiliations
Review

Implementation considerations for multisite clinical trials with cognitive neuroscience tasks

Richard S E Keefe et al. Schizophr Bull. 2008 Jul.

Abstract

Multisite clinical trials aimed at cognitive enhancement across various neuropsychiatric conditions have employed standard neuropsychological tests as outcome measures. While these tests have enjoyed wide clinical use and have proven reliable and predictive of functional disability, a number of implementation challenges have arisen when these tests are used in clinical trials. These issues are likely to be magnified in future studies when cognitive neuroscience (CN) procedures are explored in these trials, because in their current forms CN procedures are less standardized and more difficult to teach and monitor. For multisite trials, we anticipate that the most challenging issues will include assuring tester competence, monitoring tester performance, specific challenges with complex assessment methods, and having resources available for adequate monitoring of data quality. Suggestions for overcoming these implementation challenges are offered.

PubMed Disclaimer

References

    1. Mohs RC, Kim Y, Johns CA, Dunn DD, Davis KL. Assessing change in Alzheimer's disease: memory and language tests. In: Poon LW, editor. Handbook for Clinical Memory Assessment of Older Adults. Washington, DC: American Psychological Association; 1986. pp. 149–155.
    1. Davidson M, Keefe RSE. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res. 1995;17:123–129. - PubMed
    1. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25:201–222. - PubMed
    1. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176–184. - PubMed
    1. Kern RS, Green MF, Nuechterlein KH, Deng B. NIMH MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res. 2004;72:11–19. - PubMed

MeSH terms